GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

OFG · Dec 31, 2025

OFG BANCORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001030469-26-000008Bank
Sequential deposit growth75thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

2.54% · CORE · VALID

Net-income growth20thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

3.50% · CORE · VALID

Interest-income growth35thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

4.09% · CORE · VALID

Cash and equivalents65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$1.0B · CORE · VALID

Sequential loan growth55thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

1.00% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History54 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Increased
Previous
-1.34%
Current
2.54%
Delta
3.88%
Earnings Growth Decreased
Previous
10.29%
Current
3.50%
Delta
-6.80%
Interest Income Growth Decreased
Previous
5.88%
Current
4.09%
Delta
-1.79%
Liquidity Increased
Previous
$740.3M
Current
$1.0B
Delta
$300.0M
Loan Growth Increased
Previous
-0.89%
Current
1.00%
Delta
1.89%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.